Fig 1.
Enrollment, interventions and assessment chart for Group A and Group B.
Fig 2.
Schematic diagram of the randomized, cross-over protocol.
Yellow indicates the 12-week block for exoskeleton set-up and in-lab accommodation. Pink indicates the 12-week block for community exoskeleton use, including a 6-week follow up period. Blue indicates the 12-week block for standard therapy in the community.
Fig 3.
(A) Components of the NIH-Agilik exoskeleton, which includes orthotics customized to each user, an actuated knee joint, and a passive adjust ankle joint. (B) Example torque profiles applied over the gait cycle (heel-strike to heel-strike) for each exoskeleton operational mode.
Table 1.
Outcome measures by ICF domain and data collection timepoints.
Fig 4.
Pilot results showing the effect of the NIH-Agilik exoskeleton on gait biomechanics.
(A) Average knee angle across the gait cycle during over ground walking with the exoskeleton using the Zero Mode (black), Assist Mode (green), Resist Mode (red) and Interleaved Mode (blue) for a single participant with crouch gait from CP. Shaded areas indicate 1 standard deviation around the mean. (B) Average vastus lateralis (top) and semitendinosus (bottom) muscle activation for the same strides.